Bcl-2 overexpression enhances tumor-specific T-cell survival

Jehad Charo, Steven E. Finkelstein, Navrose Grewal, Nicholas P. Restifo, Paul F. Robbins, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Although immunotherapy based on the adoptive transfer of tumor-specific T lymphocytes has been shown to result in dramatic clinical responses in some patients, the relatively low levels of engraftment and persistence of the adoptively transferred cells may limit these responses in many patients. In an attempt to develop strategies for prolonging the survival of adoptively transferred T cells, we have carried out studies in which T cells obtained from healthy donors as well as tumor-specific T cells were transduced with a retrovirus expressing the human Bcl-2 gene. Our results indicate that these transduced T cells overexpress Bcl-2, are resistant to death, and have a survival advantage following interleukin-2 withdrawal compared with control T cells transduced with a retrovirus expressing green fluorescent protein. Tumor-specific T cells overexpressing Bcl-2 maintained their ability to specifically recognize and respond to target cells. Furthermore, we show that adoptive immunotherapy of an established B16 tumor can be significantly enhanced by overexpressing Bcl-2 in melanoma-specific T-cell receptor transgenic T cells. Our data suggest that adoptive immunotherapy approaches to the treatment of cancer patients may be enhanced using Bcl-2-modified tumor-reactive T cells.

Original languageEnglish (US)
Pages (from-to)2001-2008
Number of pages8
JournalCancer Research
Volume65
Issue number5
DOIs
Publication statusPublished - Mar 1 2005
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Charo, J., Finkelstein, S. E., Grewal, N., Restifo, N. P., Robbins, P. F., & Rosenberg, S. A. (2005). Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Research, 65(5), 2001-2008. https://doi.org/10.1158/0008-5472.CAN-04-2006